Opendata, web and dolomites

PERISCOPE SIGNED

PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PERISCOPE project word cloud

Explore the words cloud of the PERISCOPE project. It provides you a very rough idea of what is the project "PERISCOPE" about.

innovation    pertussis    reducing    animal    burden    human    adaptive    standardized    circulation    accelerated    optimal    shown    incidence    efpia    vaccinated    bioinformatics    differences    trials    suggesting    pathogenesis    countries    additionally    internationally    models    public    biomarkers    older    successful    vaccines    cell    unravel    vaccine    global    infection    industrialized    epidemiology    molecular    decade    accompanied    series    periscope    bp    initiate    evaluation    techniques    ecosystem    cutting    infrastructure    disease    transmission    wane    expertise    microbiology    protection    humans    strategies    innate    rebuild    reduce    ap    vaccination    immunology    immunity    vulnerable    assays    harmonized    durable    infants    colonization    risk    group    clinical    candidates    acellular    scientific    immunization    introduction    profile    registration    adults    guide    adolescents    constitutes    last    reactogenicity    edge    brings   

Project "PERISCOPE" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.periscope-project.eu
 Total cost 29˙926˙682 €
 EC max contribution 21˙000˙000 € (70%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-03-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2021-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 3˙701˙114.00
2    UNIVERSITY OF SOUTHAMPTON UK (SOUTHAMPTON) participant 2˙561˙944.00
3    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER UK (LONDON) participant 2˙048˙455.00
4    RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU NL (BILTHOVEN) participant 2˙021˙832.00
5    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙779˙999.00
6    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 1˙500˙243.00
7    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 1˙492˙500.00
8    TURUN YLIOPISTO FI (Turku) participant 1˙475˙000.00
9    INSTITUT PASTEUR DE LILLE FONDATION FR (LILLE) participant 799˙998.00
10    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) participant 650˙000.00
11    Department of Health UK (Leeds) participant 564˙110.00
12    UNIVERSIDAD DE SALAMANCA ES (SALAMANCA) participant 547˙500.00
13    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 531˙250.00
14    UNIVERSITY OF BATH UK (BATH) participant 399˙455.00
15    MIKROBIOLOGICKY USTAV AV CR V.V.I CZ (PRAHA 4) participant 300˙000.00
16    UNIVERSITE LIBRE DE BRUXELLES BE (BRUXELLES) participant 299˙995.00
17    Q-BIOLOGICALS NV BE (GENT) participant 175˙097.00
18    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 84˙380.00
19    UNITED KINGDOM RESEARCH AND INNOVATION UK (SWINDON) participant 67˙125.00
20    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 0.00
21    GLAXOSMITHKLINE BIOLOGICALS SA BE (RIXENSART) participant 0.00
22    MEDICAL RESEARCH COUNCIL UK (SWINDON) participant 0.00
23    SANOFI PASTEUR SA FR (LYON) participant 0.00
24    UNIVERSITAT BASEL CH (BASEL) participant 0.00

Map

 Project objective

Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there has been a rise in pertussis incidence, particularly in vaccinated adolescents and adults in industrialized countries. The increased circulation of B. pertussis (Bp) constitutes a risk for transmission to vulnerable infants and older adults. Additionally, immunity in humans has been shown to wane rapidly after immunization with pertussis vaccines, especially with acellular pertussis (aP) vaccines, suggesting that the improved reactogenicity profile of aP compared to whole cell pertussis vaccines, may be accompanied by differences in duration of immunity. The key objectives of PERISCOPE are to 1. identify biomarkers of protection against Bp colonization and disease; 2. foster scientific innovation and rebuild the ecosystem and technical infrastructure needed in Europe to allow the future evaluation of novel pertussis vaccine candidates and 3. improve understanding of the pathogenesis of Bp infection and its potential impact on the recently observed changes in pertussis epidemiology. To reach these objectives, PERISCOPE brings together a selected group of internationally recognized public and EFPIA partners with strong expertise in clinical trials, immunology, molecular microbiology, human and animal challenge models and bioinformatics. We will initiate a series of (pre)clinical studies and develop harmonized human and animal challenge models, standardized assays and cutting-edge techniques to unravel the innate and adaptive responses to Bp. This will allow us to identify biomarkers of protection and durable immunity. PERISCOPE will thus facilitate the accelerated development and registration of novel pertussis vaccines and/or guide optimal use of vaccination strategies. The introduction of improved pertussis vaccines will help to reduce the global burden of pertussis.

 Deliverables

List of deliverables.
External Project website Websites, patent fillings, videos etc. 2020-02-20 17:22:05
Summary report on first plenary conference with key stakeholders Documents, reports 2020-02-20 17:22:05
Dissemination toolkit Other 2020-02-20 17:22:05
PERISCOPE position paper Documents, reports 2020-02-20 17:22:05

Take a look to the deliverables list in detail:  detailed list of PERISCOPE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Mieszko M. Wilk, Lisa Borkner, Alicja Misiak, Lucy Curham, Aideen C. Allen, Kingston H. G. Mills
Immunization with whole cell but not acellular pertussis vaccines primes CD4 T RM cells that sustain protective immunity against nasal colonization with Bordetella pertussis
published pages: 169-185, ISSN: 2222-1751, DOI: 10.1080/22221751.2018.1564630
Emerging Microbes & Infections 8/1 2020-03-05
2019 Hans de Graaf, Muktar Ibrahim, Alison R Hill, Diane Gbesemete, Andrew T Vaughan, Andrew Gorringe, Andrew Preston, Annemarie M Buisman, Saul N Faust, Kent E Kester, Guy A M Berbers, Dimitri A Diavatopoulos, Robert C Read
Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing Colonization
published pages: , ISSN: 1058-4838, DOI: 10.1093/cid/ciz840
Clinical Infectious Diseases 2020-03-05
2017 Hans de Graaf, Diane Gbesemete, Andrew R. Gorringe, Dimitri A. Diavatopoulos, Kent E. Kester, Saul N. Faust, Robert C. Read
Investigating Bordetella pertussis colonisation and immunity: protocol for an inpatient controlled human infection model
published pages: e018594, ISSN: 2044-6055, DOI: 10.1136/bmjopen-2017-018594
BMJ Open 7/10 2020-02-20
2018 Lisa Borkner, Alicja Misiak, Mieszko M. Wilk, Kingston H. G. Mills
Azithromycin Clears Bordetella pertussis Infection in Mice but Also Modulates Innate and Adaptive Immune Responses and T Cell Memory
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.01764
Frontiers in Immunology 9 2020-02-20
2018 Thibaut Naninck, Loïc Coutte, Céline Mayet, Vanessa Contreras, Camille Locht, Roger Le Grand, Catherine Chapon
In vivo imaging of bacterial colonization of the lower respiratory tract in a baboon model of Bordetella pertussis infection and transmission
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-30896-7
Scientific Reports 8/1 2020-02-20
2018 Philippe Denoel, Patricia Londoño-Hayes, Magda Chlebus, Magdalena Rodriguez de Azero
Impact of the Innovative Medicines Initiative on vaccine development
published pages: 769-770, ISSN: 1474-1776, DOI: 10.1038/nrd.2018.72
Nature Reviews Drug Discovery 17/11 2020-02-20
2018 Dimitri A. Diavatopoulos, Kingston H.G. Mills, Kent E. Kester, Beate Kampmann, Marcela Silerova, Ulrich Heininger, Jacques J.M. van Dongen, Robbert G. van der Most, Martijn A. Huijnen, Emilio Siena, Nathalie Mielcarek, Martina M. Ochs, Philippe Denoël, Guy Berbers, Annemarie M. Buisman, Marien I. de Jonge, Craig Fenwick, Andrew Gorringe, Qiushui He, Dominic Kelly, Roger Le Grand, Camille Locht, Françoise Mascart, Jussi Mertsola, Alberto Orfao, Giuseppe Pantaleo, Andrew J. Pollard, Andrew Preston, Robert Read, Peter Sebo, Cecile van Els, Branislav Vecerek, Patricia Londoño-Hayes, Ronald de Groot
PERISCOPE: road towards effective control of pertussis
published pages: , ISSN: 1473-3099, DOI: 10.1016/s1473-3099(18)30646-7
The Lancet Infectious Diseases 2020-02-20

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERISCOPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERISCOPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More